

Pharmaceutical Management Agency  
New Zealand  
Pharmaceutical Schedule

# Section H Update

for Hospital Pharmaceuticals

June 2022

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a background of white wavy lines on a grey background.

PHARMAC  
TE PĀTAKA WHAIORANGA

# Contents

Summary of decisions effective 1 June 2022 .....	3
Section H changes to Part II .....	5
Index .....	9

## Summary of decisions

EFFECTIVE 1 JUNE 2022

- Atomoxetine (APO-Atomoxetine) cap 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg – new listing
- Celecoxib (Celecoxib Pfizer) cap 100 mg and 200 mg – price decrease and addition of PSS
- Clonidine hydrochloride (Clonidine Teva) tab 25 mcg – price decrease and addition of PSS
- Clonidine hydrochloride (Clonidine BNM) tab 25 mcg – to be delisted 1 November 2022
- Docusate sodium with sennosides (Laxsol) tab 50 mg with sennosides 8 mg – price decrease and addition of PSS
- Eftrenocog alfa [Recombinant factor IX] (Alprolix) inj 4,000 iu vial – new listing
- Eplerenone (Inspra) tab 25 mg – new Pharmacode listing
- Fluoxetine hydrochloride (Fluox) tab dispersible 20 mg, scored – new pack size listing
- High protein enteral feed 1.28 kcal/ml (e.g. Nutrison Protein Plus Multi Fibre) liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle – new listing
- High protein enteral feed 1.28 kcal/ml (e.g. Nutrison Protein Plus Multi Fibre) liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag – to be delisted 1 June 2023
- High protein oral feed 2.4 kcal/ml (e.g. Fortisip Compact Protein) liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle – delisting delayed
- Hydroxocobalamin (Hydroxocobalamin Panpharma) inj 1 mg per ml, 1 ml ampoule – new listing and addition of PSS
- Hydroxocobalamin (Neo-B12) inj 1 mg per ml, 1 ml ampoule – to be delisted 1 November 2022
- Iodixanol (Visipaque) inj 270 mg per ml (iodine equivalent), 50 ml and 100 ml bottle and inj 320 mg per ml (iodine equivalent), 50 ml, 100 ml and 200 ml bottle – price increase
- Iohexol (Omnipaque) inj 240 mg per ml (iodine equivalent), 50 ml bottle, inj 300 mg per ml (iodine equivalent), 20 ml, 50 ml and 100 ml bottle and inj 350 mg per ml (iodine equivalent), 20 ml, 50 ml, 75 ml, 100 ml and 200 ml bottle – price increase
- Lidocaine [lignocaine] hydrochloride (Lidocaine-Baxter) inj 1%, 20 ml vial – new listing

## Summary of decisions – effective 1 June 2022 (continued)

- Magnesium sulphate inj 100 mg per ml, 40 ml bag – new presentation listing
- Palivizumab (Synagis) inj 100 mg per ml, 1 ml vial – new listing
- Paracetamol (Biomed) suppos 25 mg and 50 mg – to be delisted 1 June 2023
- Peptide-based enteral feed 1 kcal/ml (e.g. Nutrison Advanced Peptisorb) liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bottle – new listing
- Peptide-based enteral feed 1 kcal/ml (e.g. Nutrison Advanced Peptisorb) liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag – to be delisted 1 June 2023

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

## Section H changes to Part II

Effective 1 June 2022

### ALIMENTARY TRACT AND METABOLISM

14	DOCUSATE SODIUM WITH SENNOSIDES (↓ price and addition of PSS) Tab 50 mg with sennosides 8 mg – <b>5% DV Nov-22 to 2025</b> .....3.50	200	<b>Laxsol</b>
22	MAGNESIUM SULPHATE (new presentation listing) Inj 100 mg per ml, 40 ml bag		
24	HYDROXOCOBALAMIN (brand change and addition of PSS) Inj 1 mg per ml, 1 ml ampoule – <b>5% DV Nov-22 to 2024</b> .....2.46	3	<b>Hydroxocobalamin Panpharma</b>
	Note – Neo-B12 inj 1 mg per ml, 1 ml ampoule to be delisted from 1 November 2022.		

### BLOOD AND BLOOD FORMING ORGANS

31	EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] (new listing) → Inj 4,000 iu vial.....9,800.00	1	Alprolix
----	---	---	----------

### CARDIOVASCULAR SYSTEM

46	CLONIDINE HYDROCHLORIDE (↓ price and addition of PSS) Tab 25 mcg – <b>5% DV Nov-22 to 2025</b> .....29.32	112	<b>Clonidine Teva</b>
46	CLONIDINE HYDROCHLORIDE (delisting) Tab 25 mcg.....8.75	112	Clonidine BNM
	Note – Clonidine BNM tab 25 mcg to be delisted from 1 November 2022.		
47	EPLERENONE (new Pharmacode listing) → Tab 25 mg – <b>5% DV Jun-22 to 2024</b> .....18.50	30	<b>Inspra</b>
	Note – this is a listing for Pharmacode 2619512.		

### INFECTIONS

106	CELECOXIB (↓ price and addition of PSS) Cap 100 mg – <b>5% DV Nov-22 to 2025</b> .....3.45	60	<b>Celecoxib Pfizer</b>
	Cap 200 mg – <b>5% DV Nov-22 to 2025</b> .....3.20	30	<b>Celecoxib Pfizer</b>

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 June 2022 (continued)

### NERVOUS SYSTEM

111	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (new listing) Inj 1%, 20 ml vial.....	6.20	5	Lidocaine-Baxter
	Note – this is a new Pharmacode listing, 2599856.			
113	PARACETAMOL (delisting) Suppos 25 mg – <b>1% DV Nov-19 to 2022</b> ..... Suppos 50 mg – <b>1% DV Nov-19 to 2022</b> .....	58.50 58.50	20 20	<b>Biomed</b> <b>Biomed</b>
	Note – Biomed suppos 25 mg and 50 mg brand only to be delisted from 1 June 2023.			
119	FLUOXETINE HYDROCHLORIDE (new pack size listing) Tab dispersible 20 mg, scored – <b>1% DV Feb-21 to 2022</b> .....	1.84	28	<b>Fluox</b>
128	ATOMOXETINE (new listing) Cap 10 mg ..... Cap 18 mg ..... Cap 25 mg ..... Cap 40 mg ..... Cap 60 mg ..... Cap 80 mg ..... Cap 100 mg .....	18.41 27.06 29.22 29.22 46.51 56.45 58.48	28 28 28 28 28 28 28	APO-Atomoxetine APO-Atomoxetine APO-Atomoxetine APO-Atomoxetine APO-Atomoxetine APO-Atomoxetine APO-Atomoxetine

### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

175	PALIVIZUMAB (new listing) → Inj 100 mg per ml, 1 ml vial .....	1,700.00	1	Synagis
	Restricted Initiation – RSV prophylaxis for the 2022/2023 RSV seasons, in the context of COVID-19 Paediatrician <i>Re-assessment required after 6 months</i> Either: 1 Infant was born in the last 2 years and has severe lung, airway, neurological or neuromuscular disease that requires community ventilation; or 2 Both: 2.1 Infant was born in the last 12 months; and 2.2 Any of the following: 2.2.1 Patient was born at less than 28 weeks gestation; or 2.2.2 Both: 2.2.2.1 Patient was born at less than 32 weeks gestation; and 2.2.2.2 Either: 2.2.2.2.1 Patient has chronic lung disease; or 2.2.2.2.2 Patient is Māori or any Pacific ethnicity; or			

continued...

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

## Changes to Section H Part II – effective 1 June 2022 (continued)

continued...

### 2.2.3 Both:

2.2.3.1 Patient has haemodynamically significant heart disease; and

2.2.3.2 Any of the following:

2.2.3.2.1 Patient has unoperated simple congenital heart disease with significant left to right shunt (see note a); or

2.2.3.2.2 Patient has unoperated or surgically palliated complex congenital heart disease; or

2.2.3.2.3 Patient has severe pulmonary hypertension (see note b); or

2.2.3.2.4 Patient has moderate or severe LV failure (see note c)

Note:

a) Patient requires/will require heart failure medication, and/or patient has significant pulmonary hypertension, and/or patient will require surgical palliation/definitive repair within the next 3 months

b) Mean pulmonary artery pressure more than 45 mmHg

c) LV Ejection Fraction less than 40%

Continuation – RSV prophylaxis for the 2022/2023 RSV seasons, in the context of COVID-19

Paediatrician

*Re-assessment required after 6 months*

Patient still meets initial criteria

Note – Synagis inj 100 mg per ml, 1 ml vial to be delisted from 1 January 2024.

## VARIOUS

### 234 IODIXANOL († price)

Inj 270 mg per ml (iodine equivalent), 50 ml bottle .....	232.00	10	Visipaque
Inj 270 mg per ml (iodine equivalent), 100 ml bottle .....	452.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 50 ml bottle .....	232.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 100 ml bottle .....	452.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 200 ml bottle .....	892.00	10	Visipaque

### 234 IOHEXOL († price)

Inj 240 mg per ml (iodine equivalent), 50 ml bottle .....	84.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 20 ml bottle .....	80.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 50 ml bottle .....	86.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 100 ml bottle .....	158.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 20 ml bottle .....	82.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 50 ml bottle .....	88.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 75 ml bottle .....	120.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 100 ml bottle .....	160.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 200 ml bottle .....	310.00	10	Omnipaque

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 June 2022 (continued)

### SPECIAL FOODS

- 248 PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML (new listing)  
 → Liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml,  
 1,000 ml bottle *e.g. Nutrison Advanced Peptisorb*
- 248 PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML (delisting)  
 → Liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml,  
 1,000 ml bag *e.g. Nutrison Advanced Peptisorb*
- Note – e.g. Nutrison Advanced Peptisorb liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag to be delisted from 1 June 2023.
- 250 HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML (new listing)  
 → Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and  
 1.5 g fibre per 100 ml, 1,000 ml bottle *e.g. Nutrison Protein Plus Multi Fibre*
- 250 HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML (delisting)  
 → Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and  
 1.5 g fibre per 100 ml, 1,000 ml bag *e.g. Nutrison Protein Plus Multi Fibre*
- Note – e.g. Nutrison Protein Plus Multi Fibre liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag to be delisted from 1 June 2023.
- 258 HIGH PROTEIN ORAL FEED 2.4 KCAL/ML (delisting delayed)  
 Only to be used for patients currently on or would be using Fortisip or Fortisip Multi Fibre  
 → Liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g  
 fat per 100 ml, 125 ml bottle *e.g. Fortisip Compact Protein*
- Note – e.g. Fortisip Compact Protein liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle delisting delayed until 1 December 2022.



# Index

## Pharmaceuticals and brands

<b>A</b>			
Alprolix .....	5	Iodixanol .....	7
APO-Atomoxetine.....	6	Iohexol.....	7
Atomoxetine.....	6	<b>L</b>	
<b>C</b>		Laxsol.....	5
Celecoxib.....	5	Lidocaine-Baxter .....	6
Celecoxib Pfizer .....	5	Lidocaine [Lignocaine] hydrochloride .....	6
Clonidine BNM .....	5	Lignocaine .....	6
Clonidine hydrochloride.....	5	<b>M</b>	
Clonidine Teva .....	5	Magnesium sulphate .....	5
<b>D</b>		<b>N</b>	
Docusate sodium with sennosides .....	5	Nutrison Advanced Peptisorb .....	8
<b>E</b>		Nutrison Protein Plus Multi Fibre .....	8
Eftrenonacog alfa [Recombinant factor IX] .....	5	<b>O</b>	
Eplerenone.....	5	Omnipaque .....	7
<b>F</b>		<b>P</b>	
Fluox.....	6	Palivizumab .....	6
Fluoxetine hydrochloride.....	6	Paracetamol.....	6
Fortisip Compact Protein .....	8	Peptide-based enteral feed 1 kcal/ml .....	8
<b>H</b>		<b>R</b>	
High protein enteral feed 1.28 kcal/ml.....	8	Recombinant factor IX.....	5
High protein oral feed 2.4 kcal/ml .....	8	<b>S</b>	
Hydroxocobalamin .....	5	Synagis .....	6
Hydroxocobalamin Panpharma.....	5	<b>V</b>	
<b>I</b>		Visipaque.....	7
Inspra .....	5		

New Zealand  
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

Email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

ISSN 1172-3694 (Print)

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand